Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Xbrane Biopharma AB ( (SE:XBRANE) ) has provided an announcement.
Xbrane Biopharma AB has scheduled a teleconference and webcast for investors, analysts and media on February 20, 2026, at 09:00 CET, to present its 2025 year-end report, which will be published an hour earlier that same morning. Chief executive Martin Åmark and chief financial officer and head of investor relations Jane Benyamin will lead the English-language presentation and subsequent Q&A, offering stakeholders a fresh look at the company’s financial performance and strategic progress following the European launch of its lead biosimilar Ximluci®.
The event underscores Xbrane’s efforts to maintain active engagement with the capital markets as it advances a biosimilar pipeline aimed at large reference markets and leverages its cost-efficient production platform. For shareholders and potential investors, the year-end briefing will be a key opportunity to assess how the company is executing on its growth strategy in the competitive biosimilars landscape and how its commercial rollout and pipeline developments may support future value creation.
The most recent analyst rating on (SE:XBRANE) stock is a Hold with a SEK10.50 price target. To see the full list of analyst forecasts on Xbrane Biopharma AB stock, see the SE:XBRANE Stock Forecast page.
More about Xbrane Biopharma AB
Xbrane Biopharma AB is a Sweden-based biopharmaceutical company that develops biological drugs using a patented platform technology designed to significantly lower production costs versus competing systems. The company focuses on a portfolio of biosimilar candidates targeting reference products with an estimated EUR 23 billion in combined annual peak sales, led by its ophthalmology biosimilar Ximluci®, which received European market authorization and was launched in 2023.
Average Trading Volume: 65,360
Technical Sentiment Signal: Sell
Current Market Cap: SEK218.4M
Learn more about XBRANE stock on TipRanks’ Stock Analysis page.